Castañ-Abad MT, Montserrat-Capdevila J, Godoy P Diabetes as a risk factor for severe exacerbation and death in patients with COPD: a prospective cohort study. Eur J Public Health. 2020; 30:(4)822-827

Pradhan R, Lu S, Yin H Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study. BMJ. 2022; 379

Rogliani P, Matera MG, Calzetta L Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. Respir Med. 2019; 154:86-92

Treating chronic obstructive pulmonary disease in people with type 2 diabetes

01 February 2023
Volume 5 · Issue 2

GLP-1 receptor agonists, DPP-4 inhibitors and SGLT-2 inhibitors are commonly prescribed antihyperglycaemic drugs, which are known for their favourable cardiovascular effects. However, according to Pradhan et al (2022), emerging research suggests that they may also benefit the respiratory system. There has been interest therefore in exploring whether or not these drugs could benefit the large amount of people who are living with the disabling lung condition, chronic obstructive pulmonary disease (COPD).

A new study published in the British Medical Journal has examined whether the use of the receptor agonist glucagon-like peptide 1 (GLP-1), dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose co-transporter-2 (SGLT-2) inhibitors, separately, are associated with a lower risk of COPD exacerbations among patients living with COPD and type 2 diabetes (Pradhan et al, 2022). This cohort was chosen as those with type 2 diabetes are at high risk of COPD-related morbidity and mortality (Castañ-Abad et al, 2020).

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month